Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX
Brief Summary: The Swefot trial was designed to compare two treatment strategies for patients with early rheumatoid arthritis (less than 1 year symptom duration): the use of a combination of traditional antirheumatic medications (DMARDs), versus a combination including a newer "biological" anti-TNF medication. In order to make this trial consistent with current practices in rheumatology, all patients were first given the most commonly used antirheumatic medication, methotrexate (MTX). After 3-4 months those patients who had not responded adequately to this treatment were randomized to receive either MTX plus sulfasalazine plus hydroxychloroquine, or MTX plus infliximab. Again, to be truly life-like, the trial allowed patients who could not tolerate one of the added medications to switch in treatment - but keeping with the same strategy - so that sulfasalazine plus hydroxychloroquine could be replaced by cyclosporin A, and infliximab by etanercept. The primary outcome in this trial was the percentage of patients who, after one year of treatment, achieved a "good response" as defined by Eular.


Options:
A: Inclusion Criteria:

* male/female, 18-75 years old, inclusive
* diagnosis of adult-onset RA
* had active disease
* had received methotrexate
* on a stable dose of folic acid

Exclusion Criteria:

* contraindication for methotrexate or anti-TNF
B: Inclusion Criteria:

* RA, symptom duration \< 12 months

Exclusion Criteria:

* Contraindication to any of the trial medications
C: Inclusion Criteria:

* Male or female patients ≥18 years of age, diagnosed with Rheumatoid Arthritis

Exclusion Criteria:

* Pregnant females
* Any other clinically significant disease or disorder which, in the opinion of the investigator might put the subject at risk
D: Inclusion Criteria:

* All patients must fulfill ACR classification criteria for rheumatoid arthritis.
* All patients must have been 16 years of age or older at time of diagnosis of rheumatoid arthritis.
* All patients must be 18 years of age or older at the time of entry into the study.
* All patients will have been receiving oral or subcutaneous methotrexate 15 to 25 mg/week (unless intolerant and on a minimum 10 mg/week) at a constant dose for at least 4 weeks, and on any methotrexate for no less than 12 weeks.
* All patients will have active disease as defined by a DAS28 of greater than or equal to 4.4.
* If patients are receiving corticosteroids, they must have been on stable dose (less than or equal to 10 mg prednisone or equivalent) for at least two weeks prior to screening.
* If patients are using non-steroidal anti-inflammatory drugs (NSAIDs), they must be on stable doses for at least one week prior to screening.
* If patients have taken leflunomide, cyclosporine, gold, Anakinra, azathioprine, or penicillamine in combination with methotrexate, they must have stopped this therapy at least 8 weeks prior to randomization.
* Laboratory tests must meet the following criteria within 2 weeks of randomization:

  * Serum creatinine 1.8 mg/dL
  * Hemoglobin 9 g/dL
  * WBC 3000 mc/L
  * Neutrophils 1000 mc/L
  * Platelets 100,000 mc/L
  * Serum transaminase level (AST or ALT, whichever is followed at the site) not exceeding 1.2 times upper limit of normal.
  * Albumin no less than 1.0 g/dL (10 g/L) below lower limit of normal. Anything below lower limit of normal must have been stable (or improving) for no less than 90 days. Stable is defined as changes of no more than 0.2 g/dL (2 g/L).
* All patients must be capable of giving informed consent and able to adhere to study visit schedule.
* Subject or designee must have the ability to self-inject investigational product or have a caregiver who can inject subcutaneous injections
* Subjects must meet one of the following criteria with regard to tuberculosis. PPD must be within 180 days of randomization if the patient has no recent exposure/travel history, or within 90 days if the patient has a recent exposure/travel history.

  * Negative PPD; or
  * Positive PPD \<5 mm, with a negative chest x-ray; or
  * Positive PPD \>5mm, treated for at least 28 days with INH.
* Subjects with an Erythrocyte sedimentation rate (ESR) of less than or equal to 10 and a tender and swollen joint count of at least 10 and does not qualify for the study using the DAS28, will be allowed to use the DAS28-CRP rather than the traditional DAS28 to determine eligibility.

Exclusion Criteria:

* Previous intolerance to methotrexate (unless able to tolerate at least 10 mg/week)
* Sensitivity to study medications
* Previous treatment with methotrexate, sulfasalazine or hydroxychloroquine in combination with each other for longer than 4 weeks duration. No combination use is allowed within 4 weeks of screening.
* No bed or wheelchair-bound patients
* Previous treatment with a TNF- inhibitor (etanercept, infliximab or adalimumab) for more than 5 weeks of therapy. Previous treatment with TNF- inhibitor must have been stopped for reasons other than toxicity or efficacy. No TNF- inhibitor therapy is allowed within the following time frames:

  * Last dose of etanercept must have been at least 4 weeks before screening.
  * Last dose of adalimumab or infliximab must have been at least 8 weeks prior to screening.

Example of an eligible patient: A patient found he could not afford the co-pays for a TNF inhibitor after two doses and stopped taking the medication two months before being evaluated for this trial.

* Evidence of important acute or chronic infections (no IV antibiotics within 1 month, and no PO antibiotics within 2 weeks)
* Pregnant or nursing women
* Women of childbearing potential or their partners who are not practicing an acceptable form of birth control as defined by investigator
* Active substance abuse or psychiatric illness likely to interfere with protocol completion
* History of multiple sclerosis, transverse myelitis, or optic neuritis
* History of macular degeneration unless patient has letter from their ophthalmologist that will allow for participation in trial
* New York Heart Association Class III or IV congestive heart failure
* Active malignancy (other than in situ cervical cancer or non-melanoma skin cancer), or history of lymphoma
* History of HIV
* History of any opportunistic infection - to include but not limited to Pneumocystis carinii, aspergillosis, histoplasmosis, or atypical mycobacterium
* History of porphyria
* Diagnosis of SLE or seronegative spondyloarthropathy or any other form of concomitant arthritis (osteoarthritis is permitted)
* Diagnosis of psoriasis unless rheumatoid factor positive
* Any significant unstable medical condition considered a contraindication by investigator
* Any participation in another investigational drug study during the 90 days preceding randomization.
* Receipt of a live vaccine within 90 days of study entry.
* History of oral or IV cyclophosphamide use
* Life expectancy less than 2 years
* Receipt of steroid injection, intravenous, intramuscular, or intraarticular, within 30 days of randomization.

Answer: B